Insights from Pharmacovigilance: Gastrointestinal-Related Immune Checkpoint Inhibitor Adverse Events

Gastroenterology. 2020 Oct;159(4):1195-1200.e1. doi: 10.1053/j.gastro.2020.06.093. Epub 2020 Jul 15.

Authors

Stephen W Reese¹, Maya Marchese¹, Julia McNabb-Baltar²

Affiliations

¹ Brigham and Women's Hospital, Department of Surgery, Center for Surgery and Public Health, Harvard Medical School, Boston, Massachusetts.
² Division of Gastroenterology, Hepatology, and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

PMID: 32681919
DOI: 10.1053/j.gastro.2020.06.093

No abstract available

MeSH terms

Adolescent
Adult
Aged
Antineoplastic Agents, Immunological / adverse effects*
Databases, Factual
Female
Gastrointestinal Diseases / chemically induced*
Gastrointestinal Diseases / diagnosis
Gastrointestinal Diseases / epidemiology
Global Health
Humans
Immune Checkpoint Inhibitors / adverse effects*
Male
Middle Aged
Pharmacovigilance*
Prognosis
Retrospective Studies
Risk Assessment
Risk Factors
Severity of Illness Index
Time Factors
Young Adult

Substances

Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors